Back to Freepaper Session

Six-month follow-up of a new intracorneal inlay for the treatment of presbyopia

Session Details

Session Title: Intracorneal inlays for correction of presbyopia

Session Date/Time: Tuesday 08/10/2013 | 08:00-10:30

Paper Time: 09:00

Venue: Main Lecture Hall (Ground Floor)

First Author: : C.Baily IRELAND

Co Author(s): :    M. O"Keefe               Melles

Abstract Details

Purpose:

To clinically evaluate the effect of the ICOLENS corneal inlay in the treatment of presbyopia at one year.

Setting:

Department of Refractive Surgery, Mater Private Hospital, Dublin, Ireland.

Methods:

A prospective non-randomised clinical study. The inlay has been inserted in the non-dominant eye of 52 eyes through a femtosecond-created pocket. Inclusion criteria included emmetropia (spherical equivalent:-0.5 to +0.75), unambiguous ocular dominance, pupil diameter between 2.4 to 4.2 mm at photopic illumination, central corneal thickness >500µm and uncorrected near visual acuity (UNVA) of 0.4logMAR (20/50) in the non-dominant eye. The optical principle utilised is that of a bifocal lens with a central zone for distance VA and a peripheral optical zone for near VA. Outcome measurements included uncorrected near and distance visual acuity and complication rate.

Results:

The mean UNVA in the surgical eye improved preoperatively from N18/N24 to N8 postoperatively (p = 0.000) with 51 patients (98%) reading N16 or better and 14 patients (27%) reading N5 or better. The mean ± SD logMAR UDVA in the surgical eye increased from 0.04 ± 0.13 preoperatively to 0.23 ± 0.15 postoperatively (p = 0.000). There was a mean ± SD loss of 1.69 ± 2.04 lines of vision (p = 0.000). Binocularly there was a mean ± SD gain of 0.56 ± 1.01 lines of vision postoperatively (p = 0.000) with 24 patients (46%) gaining ? 1 line. There were 11 implants explanted due to minimal improvement in UNVA. There were no significant adverse events reported throughout the study.

Conclusions:

Implantation of the ICOLENS corneal inlay was a safe and reversible procedure that provided a significant improvement in UNVA associated with a variable loss of monocular UDVA at six months. One year results to follow.

Financial Interest:

NONE